Project Grant R01CA315895
Award Date 9/3/26
Completion Date 8/31/31
Dollars Obligated $622K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- The National Cancer Institute awarded the Regents of the University of Michigan $646,881 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small-molecule inhibitors of ASH1L, a histone methyltransferase, as a therapeutic strategy for acute leukemia. The funded research targets acute myeloid leukemia (AML), which carries a five-year survival rate of approximately 27% with current treatments. The work focuses on blocking expression of HOX genes—particularly...
- The National Cancer Institute awarded the Regents of the University of Michigan $646,920 on March 11, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing) to conduct research on novel multi-targeted therapeutic strategies targeting T-cell lymphomas and their microenvironment. The funded work addresses chemotherapy-resistant T-cell lymphomas, where current treatments produce poor durable responses and clinical trial participation remains standard care. The...
- The National Cancer Institute awarded the University of Chicago $547,740 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to define the molecular mechanisms by which the MLL1 histone modification complex and the long noncoding RNA HOTTIP interact in acute myeloid leukemia pathogenesis. The research examines whether non-specific RNA binding to the WDR5 subunit of the MLL1 complex inhibits the complex's histone methyltransferase activity and whether the RBBP5...
- The National Cancer Institute awarded the Regents of the University of Michigan $401,115 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate novel therapeutic strategies targeting the enhancer landscape in high-risk T-cell lymphomas. The research addresses T-cell lymphomas driven by the transcription factor GATA-3, which remain largely incurable with existing therapies. The project characterizes GATA-3-dependent enhancers and evaluates P300/CBP bromodomain...
- The National Cancer Institute awarded the University of Wisconsin - Madison $699,587 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize the molecular mechanisms by which MLL-partial tandem duplication (MLLPTD) drives acute myeloid leukemia and myelodysplastic syndromes. The project leverages targeted mass spectrometry and newly developed antibodies to define how allelic complexity modifies MLLPTD protein interactions, chromatin binding, and gene regulatory...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $669,278 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop microbial-based cancer therapeutics engineered to deliver localized immune activation while minimizing systemic toxicity. The research focuses on nonpathogenic, tumor-tropic E. coli engineered to display membrane-anchored cytokines, specifically decoy-resistant...
- The National Cancer Institute awarded the University of Alabama at Birmingham $576,965 on August 15, 2026, under the Cancer Biology Research program (CFDA 93.396) to decipher and target epigenetic accessory proteins in acute myeloid leukemia. The project investigates epigenetic complexes composed of catalytic core enzymes and accessory proteins that regulate gene expression and contribute to cancer development. Most existing therapies target catalytic cores, often causing widespread chromatin...
- The National Cancer Institute awarded the Regents of the University of Michigan $646,671 under the Cancer Treatment Research program (CFDA 93.395) on May 15, 2026, to identify and validate payload candidates that maximize multiple immune-activation mechanisms in high-avidity low-affinity antibody-drug conjugates (ADCs) for combination immunotherapy in cancer treatment. The research addresses a critical gap in ADC development: existing mouse syngeneic models show poor sensitivity to ADC payloads,...
- The National Institutes of Health National Cancer Institute awarded the Regents of the University of Michigan $571,735 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA312636). The award funds research into mechanisms by which collagen extracellular matrix disruption potentiates anti-glioma immune responses. The project combines collagen inhibition with immune-stimulatory gene therapy—specifically AD-HSV1-TK to increase tumor antigen release and...
- The National Cancer Institute awarded Regents of the University of Michigan $660,808 on April 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate tissue-resident memory T cell responses in melanoma patients and their durability following immunotherapy treatment. The work will examine how tissue-resident memory T cells with high interferon gamma expression (TRM-IFNG), established at the time of primary melanoma diagnosis, are recalled and expanded to mediate...